Thyroid Hormone Receptor Inhibitor

Methimazole (Thiamazole) is an anti-thyroid agent, which blocks thyroid hormone production from the thyroid gland. Metamizol can cause hepatotoxicity.

Propylthiouracil (6-n-Propylthiouracil), a thioamide antithyroid agent, is an orally active thyroperoxidase and type-1 deiodinase (DIO1) inhibitor. Propylthiouracil can be used for the Graves disease and hyperthyroidism research.

α-Methyltyrosine methyl ester hydrochloride is an orally active and competitive tyrosine hydroxylase inhibitor. α-Methyltyrosine methyl ester hydrochloride can inhibit the conversion of tyrosine to dopamine. α-Methyltyrosine methyl ester hydrochloride causes kidney damage and urethral calculi in rats. α-Methyltyrosine methyl ester hydrochloride can be used as a tool for sympathetic nervous system research.

KB130015 (KB015) is an orally active and potent ThRα and ThRβ (thyroid hormone receptor) inhibitor, with IC₅₀ values of 4.5 and 5.1 μM, respectively. KB130015 markedly slows the kinetics of inactivation of Na⁺ channels. KB130015 activates hERG1 channels (EC₅₀ = 12.2 μM) and large-conductance Ca²⁺-activated K⁺ (BKCa) channels formed by hSlo1 (α) subunits in HEK 293 cells. KB130015 has antiarrhythmic properties. KB130015 can be used for the study of cardiovascular disease.

Octinoxate (Octyl methoxycinnamate) is a thyroid hormone receptor agonist, reducing the levels of triiodothyronine (T3) and thyroxine (T4) and transcription levels of genes related to type II deiodinase (deio2) in Japanese Medaka. Octinoxate is commonly used as a safe ultraviolet (UV) filter used in the aquatic environment. Octinoxate inhibits CYP1A1 and CYP1B1 to regulate hyaluronan (HA) (HY-B0633A) metabolism in a PI3K pathway-dependent manner in human keratinocytes. Octinoxate also exhibits an anti-estrogenic and anti-androgenic effect in vitro and in vivo.

TI17 is an inhibitor of the thyroid hormone receptor-interacting protein Trip13 and has anticancer activity. TI17 effectively inhibits multiple myeloma (MM) cell proliferation and induces cell cycle arrest and apoptosis. Trip13 is an AAA-ATPase that mediates double-strand break (DSB) repair; TI17 inhibits Trip13 function and increases DNA damage.

(Glu2)-TRH, a metabolically stable analogue of Thyrotropin-releasing hormone (TRH; HY-P0002), is a negative modulator for the cholinergic effect of TRH in the mouse brain. (Glu2)-TRH significantly attenuates TRH-induced hippocampal extracellular acetylcholine release. (Glu2)-TRH is not metabolized by thyroliberinase. (Glu2)-TRH manifests neuroprotective, antidepressant, anticonvulsant in the CNS.

Debutyldronedarone hydrochloride (SR35021 hydrochloride) is a Cytochrome P450 enzyme inhibitor and a Thyroid Hormone Receptor inhibitor, and it is a metabolite of Dronedarone (HY-A0016). Debutyldronedarone hydrochloride inhibits the binding of T3 to TRα1 and TRβ1. Debutyldronedarone hydrochloride reduces the incidence of reperfusion-induced ventricular fibrillation in anesthetized rats, while decreasing their heart rate and blood pressure. Debutyldronedarone hydrochloride can be used in studies related to ventricular fibrillation and atrial fibrillation.

Methimazole-d₃ is a deuterium labeled Methimazole (HY-B0208). Methimazole (Thiamazole) is an anti-thyroid agent, which blocks thyroid hormone production from the thyroid gland. Metamizol can cause hepatotoxicity.

Progoitrin is an orally active glucosinolate. As the precursor of goitrin (HY-N0224A), an antithyroid compound, progoitrin releases goitrin via hydrolysis by myrosinase or gastrointestinal glucosidase. Progoitrin converts to goitrin in vivo and exerts antithyroid activity by inhibiting the accumulation of radioactive iodine in the thyroid gland. Progoitrin can be used in the research of Graves' disease (thyrotoxicosis).

Metamizol (Methamizole) is an anti-thyroid agent, which blocks thyroid hormone production from the thyroid gland. Metamizol can cause hepatotoxicity.

Debutyldronedarone-d₆ hydrochloride (SR35021-d₆ hydrochloride) is the deuterated-labeled Debutyldronedarone (HY-12753). Debutyldronedarone (SR35021) is a Cytochrome P450 enzyme inhibitor and a Thyroid Hormone Receptor inhibitor, and it is a metabolite of Dronedarone (HY-A0016). Debutyldronedarone inhibits the binding of T3 to TRα1 and TRβ1. Debutyldronedarone reduces the incidence of reperfusion-induced ventricular fibrillation in anesthetized rats, while decreasing their heart rate and blood pressure. Debutyldronedarone can be used in studies related to ventricular fibrillation and atrial fibrillation.

1α-Hydroxy-3-epi-vitamin D3 (Standard) is the analytical standard of 1α-Hydroxy-3-epi-vitamin D3 (HY-10003A). This product is intended for research and analytical applications. 1α-Hydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone (PTH) secretion.

Debutyldronedarone-d₇ hydrochloride (SR35021-d₇ hydrochloride) is the deuterated-labeled Debutyldronedarone (hydrochloride) (HY-12753A). Debutyldronedarone hydrochloride (SR35021 hydrochloride) is a Cytochrome P450 enzyme inhibitor and a Thyroid Hormone Receptor inhibitor, and it is a metabolite of Dronedarone (HY-A0016). Debutyldronedarone hydrochloride inhibits the binding of T3 to TRα1 and TRβ1. Debutyldronedarone hydrochloride reduces the incidence of reperfusion-induced ventricular fibrillation in anesthetized rats, while decreasing their heart rate and blood pressure. Debutyldronedarone hydrochloride can be used in studies related to ventricular fibrillation and atrial fibrillation.

Debutyldronedarone (SR35021) is a Cytochrome P450 enzyme inhibitor and a Thyroid Hormone Receptor inhibitor, and it is a metabolite of Dronedarone (HY-A0016). Debutyldronedarone inhibits the binding of T3 to TRα1 and TRβ1. Debutyldronedarone reduces the incidence of reperfusion-induced ventricular fibrillation in anesthetized rats, while decreasing their heart rate and blood pressure. Debutyldronedarone can be used in studies related to ventricular fibrillation and atrial fibrillation.

TRIP13-IN-1 (compound 20) is a potent ligand and inhibitor of TRIP13, demonstrating anti-cancer effects both in vitro and in vivo.

Debutyldronedarone-d7 (SR35021-d7) is the deuterated-labeled Debutyldronedarone (HY-12753). Debutyldronedarone (SR35021) is a Cytochrome P450 enzyme inhibitor and a Thyroid Hormone Receptor inhibitor, and it is a metabolite of Dronedarone (HY-A0016). Debutyldronedarone inhibits the binding of T3 to TRα1 and TRβ1. Debutyldronedarone reduces the incidence of reperfusion-induced ventricular fibrillation in anesthetized rats, while decreasing their heart rate and blood pressure. Debutyldronedarone can be used in studies related to ventricular fibrillation and atrial fibrillation.

Debutyldronedarone hydrochloride (Standard) (SR35021 hydrochloride (Standard)) is the analytical standard of Debutyldronedarone (hydrochloride) (HY-12753A). This product is intended for research and analytical applications. Debutyldronedarone hydrochloride (SR35021 hydrochloride) is a Cytochrome P450 enzyme inhibitor and a Thyroid Hormone Receptor inhibitor, and it is a metabolite of Dronedarone (HY-A0016). Debutyldronedarone hydrochloride inhibits the binding of T3 to TRα1 and TRβ1. Debutyldronedarone hydrochloride reduces the incidence of reperfusion-induced ventricular fibrillation in anesthetized rats, while decreasing their heart rate and blood pressure. Debutyldronedarone hydrochloride can be used in studies related to ventricular fibrillation and atrial fibrillation.

L-6424 inhibits T3 binding to α1-T3R and β1-T3R.

D-thyroxine (D-T4) sodium is an orally active thyroid hormone that inhibits the secretion of TSH. D-thyroxine sodium can inhibit goiter, promote metamorphosis of tadpoles and influence cholesterol metabolism. D-thyroxine sodium can be used for the study of hypercholesterolemia.